Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells

被引:6
|
作者
Chorostowska-Wynimko, J
Swiercz, R
Skrzypczak-Jankun, E
Selman, SH
Jankun, J
机构
[1] Natl Inst TB & Lung Dis, Dept Lab Diagnost & Immunol, PL-01138 Warsaw, Poland
[2] Med Coll Ohio, Urol Res Ctr, Dept Urol, Toledo, OH 43699 USA
[3] Med Coll Ohio, Dept Physiol & Mol Med, Toledo, OH 43699 USA
关键词
plasminogen activator inhibitor type-1; endothelial cells; urokinase; in vitro angiogenesis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasminogen activator inhibitor type-1 (PAI-1) is considered one of the key regulators of tumor invasion, metastasis, as well as cancer-related angiogenesis. The literature suggests that PAI-1 plays a dual role in these processes because it inhibits plasmin-originated proteolysis and binds to vitronectin or integrins. Stimulation or inhibition of angiogenesis largely depends on which of these elements PAI-1 interacts. Wild PAI-1 converts quickly into its latent, inactive form and loses its anti-proteolytic activity, but still binds to vitronectin and integrins. Thus we constructed PAI-1s with extended half-life to prolong their anti-proteolytic activity. We have analyzed the effects of sprout formation inhibition by PAI-1s on two functionally different endothelial cell (EC) systems, human umbilical vein endothelial cells (HUVEC), expressing moderate amounts of urokinase (uPA), and human lung microvascular endothelial cells (HLMVEC), expressing high amounts of this enzyme. We have used wild-type PAI-1 (wPAI-1) (t(1/2) = 1.6 h) and PAI-1 cysteine mutants (CysPAI-1) characterized by their prolonged half-life time (hDbetaT) (t(1/2) = 63.6 h and t(1/2) = 7,000 h). We have observed a significant inhibitory dose-dependent effect exerted by the CysPAI-1s on sprout formation by HUVEC and HLMVEC cells. The inhibition rate was considerably stronger in lung capillary cell cultures and significantly more pronounced For CysPAI-1 mutants with longer anti-uPA activity (betaT). wPAI-1 with a short anti-proteolytic half-life has induced sprout formation in HUVEC, but not in HLMVEC cultures. This difference in behavior was most likely related to the presence of excessive amounts of uPA in HLMVEC cells and the known mechanism of clearing PAI-1/uPA/uPAR complexes from the cell surface. A less efficient system of HUVEC cells might give wPAI-1 the chance to interact with non-proteolytic pathways of angiogenesis stimulation. We conclude that while the anti-proteolytic properties of PAI-1 constructs are preserved, these proteins inhibit angiogenesis and inhibitory activity dominates over any stimulatory effects of PAI-1.
引用
收藏
页码:1155 / 1162
页数:8
相关论文
共 50 条
  • [1] HUMAN FIBROBLASTS DOWN-REGULATE PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 EXPRESSION AND UP-REGULATE TISSUE FACTOR PATHWAY INHIBITOR IN HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS
    ZHANG, JC
    WOJTA, J
    BINDER, BR
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 902 - 902
  • [2] SENESCENCE-DEPENDENT REGULATION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN HUMAN VASCULAR ENDOTHELIAL-CELLS
    COMI, P
    CHIARAMONTE, R
    MAIER, JAM
    EXPERIMENTAL CELL RESEARCH, 1995, 219 (01) : 304 - 308
  • [3] HYPERTHERMIA STIMULATES PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS INVITRO
    WOJTA, J
    HOLZER, M
    HUFNAGL, P
    CHRIST, G
    HOOVER, RL
    BINDER, BR
    AMERICAN JOURNAL OF PATHOLOGY, 1991, 139 (04): : 911 - 919
  • [4] Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 is increased by interleukin-33 in human endothelial cells
    Demyanets, S.
    Stojkovic, S.
    Kaun, C.
    Lemberger, C. E.
    de Martin, R.
    Maurer, G.
    Huber, K.
    Wojta, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : E13 - E13
  • [5] Interleukin-33 induces urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in human endothelial cells in vitro
    Stojkovic, S.
    Kaun, C.
    Maurer, G.
    Huber, K.
    Wojta, J.
    Demyanets, S.
    CARDIOVASCULAR RESEARCH, 2012, 93 : S35 - S36
  • [6] Interleukin-33 induces urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in human endothelial cells in vitro
    Demyanets, S.
    Stojkovic, S.
    Kaun, C.
    Maurer, G.
    Huber, K.
    Wojta, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 481 - 481
  • [7] Human fibroblasts downregulate plasminogen activator inhibitor type-1 in cultured human macrovascular and microvascular endothelial cells
    Zhang, JC
    Fabry, A
    Paucz, L
    Wojta, J
    Binder, BR
    BLOOD, 1996, 88 (10) : 3880 - 3886
  • [8] Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis
    Offersen, Birgitte Vrou
    Pfeiffer, Per
    Andreasen, Peter
    Overgaard, Jens
    LUNG CANCER, 2007, 56 (01) : 43 - 50
  • [9] Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells
    Lopez, S
    Peiretti, F
    Bonardo, B
    Juhan-Vague, I
    Nalbone, G
    ATHEROSCLEROSIS, 2000, 152 (02) : 359 - 366
  • [10] INDUCTION OF SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN HUMAN HEPATIC AND ENDOTHELIAL-CELLS
    FUJII, S
    LUCORE, CL
    HOPKINS, WE
    BILLADELLO, JJ
    SOBEL, BE
    THROMBOSIS AND HAEMOSTASIS, 1990, 64 (03) : 412 - 419